EASL - The International Liver Congress 2015 50th annual Meeting of the European association for the Study of the Liver Vienna, austria april 22-26 Reported by Jules Levin EASL 2015 April 22-26 Vienna Austria Stefan Zeuzem* 1, Reem Ghalib2, K. National AIDS Treatment Advocacy Project, 2 days ago
A Phase 1 Study to Evaluate the Interaction of HCV NS5B Inhibitor MK-3682 With HCV NS3/4A Protease Inhibitor MK-5172 and HCV NS5A Inhibitor MK-8408 in Healthy Subjects - National AIDS Treatment Advocacy Project, 3 days ago
C-SALVAGE: GRAZOPREVIR (GZR; MK-5172), ELBASVIR (EBR; MK-8742) AND RIBAVIRIN (RBV) FOR CHRONIC HCV-GENOTYPE 1 (GT1) INFECTION AFTER FAILURE OF DIRECT-ACTING ANTIVIRAL (DAA) THERAPY - National AIDS Treatment Advocacy Project, 3 days ago
VIENNA — Howard Monsour Jr., MD, chief of hepatology, Houston Methodist Hospital, Texas, discussed results of the C-SURFER trial, where 99% of patients with advanced chronic kidney disease treated with grazoprevir and elbasvir for chronic ...Orthopedics Today, 1 day ago
VIENNA — Patients with cirrhosis as well as genotype 1 and genotype 3 HCV responded favorably to 8 weeks of treatment with a novel grazoprevir and elbasvir-based combination regimen, according to findings presented at the 2015 International Liver ...Orthopedics Today, 1 day ago C-EDGE: Grazoprevir/elbasvir regimen yields high SVR rates in patients with HCV Orthopedics Today, 2 days ago C-SALT: Child-Pugh B patients responded to grazoprevir/elbasvir Orthopedics Today, 2 days ago
VIENNA — The goal of HCV therapy is to eradicate infection, according to Jean-Michel Pawlotsky, MD, PhD, Coordinator of the panel that published the 2015 EASL Recommendations on the Treatment of HCV. Pawlotsky, who is a professor at the ...Orthopedics Today, 2 days ago
249th ACS National Meeting & Exposition March 22-26, 2015 Denver, CO EurekAlert! provides embargoed and breaking science news you can't afford to miss. EurekAlert! offers a one-stop science news distribution service you can trust. EurekAlert! ...EurekAlert!, 2 days ago
Apr. 20, 2015 1:23 PM ET | About: Achillion Pharmaceuticals, Inc. (ACHN), Includes: GILD, MRK by: Steven Giardino Summary It is rare to have 3 or more pps moving catalysts on schedule from one company all within 8 months, but such is the case ...Seeking Alpha, 6 days ago
MERCK : Study Data from Merck & Company Update Knowledge of Hepatitis C Virus [Efficacy and safety of 8 weeks versus 12 weeks of treatment with...
Study Data from Merck & Company Update Knowledge of Hepatitis C Virus [Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus ...] ...4 Traders, 1 week ago Merck & Co. (MRK) Can't Catch a Break for Sugammadex, Faces Third FDA Rejection 3/17/2015 ClinicSpace, 1 month ago MERCK & CO., INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations. Pharmacy Choice, 1 month ago
Review Big cat offers plenty of creature comforts By admin April 13, 2015 The Pros and Cons WHATS BEST: Interior craftsmanship, wow factor from friends and colleagues WHATS WORST: The price but packages are reasonable for what you get ...Wheels.ca, 1 week ago
Quality matters. That's particularly true when buying stocks for their dividends. Some stocks claim high yields, but those dividends consume such a large percentage of the company's earnings that continued payout could be in jeopardy. The health ...Motley Fool, 2 weeks ago
After rescinding breakthrough designation earlier this year, the FDA re-established two new designations for an oral combination tablet of grazoprevir/elbasvir for the treatment of chronic hepatitis C virus infection genotype 4 and genotype 1 with ...Orthopedics Today, 2 weeks ago Two HCV Treatments Lose Breakthrough Therapy Designation Orthopedics Today, 1 month ago
on your WebpageAdd Widget >Get your members hooked!